Table 1. Characteristics of the selected studies in the analysis.
| Study [year] | Trial | Phase | Patients | TNBC patients | PD-L1+ patients | Age, mean [range] | Race | Drug | Dose | Clinical setting | Combined with | Line of therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peter Schmid [2018] | IMpassion130 | III | 451 | 451 (100%) | 185 (41.02%) | 55 [20–82] | White, Asian, Black, Native American, Hawaiian or other Pacific Islander, Multiple and Unknown | Atezolizumab | 800 mg | d1 and d15, q4w, iv, minimum 1 cycle | Nab-paclitaxel, 100 mg/m2, d1, 8, 15, q4w, 6 cycles or more | 1 line |
| Sylvia Adams [2018] | GP28328 | Ib | 33 | 33 (100%) | 12 (36.36%) | 55 [32–84] | White, Black or African American, Asian, Mutiple, Other | Atezolizumab | 800 mg | d1 and d15, q2w, iv, minimum 4 cycles | Nab-paclitaxel, 125 mg/m2, d1, 8, 15, q4w, minimum 4 cycles | 1+ line |
| Luc Y. Dirix [2017] | JAVELIN | Ib | 168 | 58 (34.52%) | 85 (50.60%) | 55 [31–81] | White, Black or African American, Asian, Other | Avelumab | 10 mg/kg | d1, q2w, iv, minimum 1 cycle | Single-agent | 2+ line |
| Leisha A. Emens [2018] | PCD4989g | I | 116 | 116 (100%) | 91 (78.45%) | 53 [29–82] | Not mentioned | Atezolizumab | 15 or 20 mg/kg, or at a 1,200-mg flat dose | d1, q3w, iv, minimum 1 cycle | Single-agent | 1+ line |
| Rita Nanda [2016] | KEYNOTE-012 | Ib | 32 | 32 (100%) | 32 (100%) | 50.5 [29–72] | White, Black or African American | Pembrolizumab | 10 mg/kg | d1, q2w, iv, minimum 1 cycle | Single-agent | 1+ line |
| Sylvia Adams [2018] | KEYNOTE-086 cohort A | II | 170 | 170 (100%) | 105 (61.76%) | 53.5 [28–85] | NR | Pembrolizumab | 200 mg | d1, q3w, iv, minimum 1 cycle, up to 2 years | Single-agent | 2+ line |
| Sylvia Adams [2018] | KEYNOTE-086 cohort B | II | 84 | 84 (100%) | 84 (100%) | 52.5 [26–91] | NR | Pembrolizumab | 200 mg | d1, q3w, iv, minimum 1 cycle, up to 2 years | Single-agent | 1 line |
| Sherene Loi [2019] | PANACEA | Ib-II | 58 | 0 (0%) | 46 (79.31%) | NR | NR | Pembrolizumab | Phase Ib: 2 mg/kg or 10 mg/kg; Phase II: 200 mg | d1, q3w, iv, minimum 1 cycle, up to 2 years | Trastuzumab, 6 mg/kg | 1+ line |
| Hope S. Rugo [2018] | KEYNOTE-028 | Ib | 25 | 0 | 25 (100%) | 53 [36–79] | White, Asian, Black or African American, and not specified | Pembrolizumab | 10 mg/kg | d1, q2w, iv, minimum 1 cycle, up to 2 years | Single-agent | 1+ line |
TNBC, triple-negative breast cancer; PD-L1, programmed death-ligand 1; NR, not reported.